1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Cochlear Limited

Cochlear Limited

CHEOF
Cochlear LimitedUS flagOther OTC
81.42
USD
- -
- -
5.32BMarket Cap
Cochlear Limited
CHEOF
(Other OTC)

Recent

price

81.42

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
13.06
14.31
13.71
13.23
14.14
16.25
19.78
21.85
23.71
24.73
22.14
22.78
25.06
29.44
34.11
35.81
Revenue per Share
2.76
3.18
1
2.33
1.65
2.56
3.31
3.9
4.27
4.8
-4
4.97
4.4
4.57
5.44
5.94
Basic EPS, GAAP
1.55
1.96
2.3
0.34
1.4
2.81
2.58
3.29
-0.86
-1.99
-2.19
-1.1
-1.17
-1.46
-1.37
-1.57
Free Cash Flow per Basic Share
1.9
2.1
2.4
2.51
2.55
2.17
2.1
2.5
2.8
3.15
3.25
1.15
2.95
3
3.75
4.25
Dividend per Share
7.44
8.54
7.15
7.01
6.35
6.7
8.11
9.7
11.21
12.85
23.29
25.01
26.33
27.46
28.57
29.85
Book Value per Share
4.02
5.21
3.14
2.13
1.67
2.23
3.92
3.55
4.62
5.23
16.62
19.76
19.66
19.84
21.2
22.15
Tangible Book Value per Share
56
57
57
57
57
57
57
57
58
58
60
66
66
66
66
65
Basic Weighted Avg Shares
735
810
779
753
805
926
1,131
1,254
1,364
1,427
1,321
1,498
1,648
1,936
2,236
2,343
Sales/Revenue/Turnover
29.45
29.52
16.27
21.93
12.52
18.55
19.01
22.33
22.45
21.52
11.34
15.49
17.95
16.11
18.52
17.33
Operating Margin (%)
- -
- -
16
15
27
30
33
31
34
38
78
80
73
81
85
90
Depreciation Expense
155
180
57
133
94
146
189
224
246
277
-238
326
289
301
357
389
Net Income, GAAP
25.89
23.4
21.28
23.21
19.98
25.71
25.7
27.59
27.81
24.32
- -
10.72
26.59
24.21
26.4
25
Effective Tax Rate (%)
21.11
22.25
7.29
17.61
11.64
15.76
16.71
17.83
18.02
19.39
-18.04
21.8
17.54
15.53
15.96
16.6
Profit Margin (%)
235
206
112
213
251
86
280
137
287
276
660
828
799
784
821
814
Working Capital
83
3
20
167
234
45
189
134
144
178
285
232
175
163
202
194
LT Debt
438
503
385
357
329
355
449
544
611
726
1,402
1,702
1,686
1,749
1,840
1,950
Total Equity
27.52
30.74
18.94
25.26
14.56
21.93
25.67
26.51
26.72
26.97
- -
10.12
11.04
12.05
14.97
14.12
Return on Invested Capital (%)
29.07
33.29
12.1
26.48
17.46
25.74
31.26
30.21
30.49
32.73
- -
16.85
15.17
15.41
17.63
18.45
Return on Capital (%)
39.5
39.92
12.77
32.93
24.66
39.26
44.73
43.86
40.93
39.93
-22.38
21.53
17.13
16.99
19.4
20.33
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.71%
7.09%
5.97%
Free Cash Flow
3.21%
-1.18%
14.25%
Net Income, GAAP
-33.25%
-43.36%
9%
Sales/Revenue/Turnover
10.02%
12.24%
4.81%
Total Cash Common Dividend
18.32%
27.02%
13.23%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,936
2024
- -
- -
- -
- -
2,236
2025
- -
- -
- -
- -
2,343

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4.57
2024
- -
- -
- -
- -
5.44
2025
- -
- -
- -
- -
5.94

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3
2024
- -
- -
- -
- -
3.75
2025
- -
- -
- -
- -
4.25
Similar Companies
Tivic Health Systems, Inc. (TIVC)
Braster S.A. (BRA.WA)
Titan Medical Inc. (TMDIF)
Novacyt S.A. (NVYTF)
Hemcheck Sweden AB (publ) (HEMC.ST)
Manhattan Scientifics, Inc. (MHTX)
Business
Cochlear Limited (ASX: COH; OTC: CHEOF) develops, manufactures, and markets implantable hearing solutions for recipients with severe-to-profound hearing loss. The company offers a comprehensive portfolio of cochlear implant systems, including the Nucleus implant family with advanced sound processors such as the Nucleus 8, Nucleus 7, and Kanso 2; bone conduction implants like the Baha 6 Max and Baha 5; and bimodal hearing solutions integrating Cochlear implants with hearing aids. Additional services encompass surgical planning tools, rehabilitation programs, telehealth support, and connectivity accessories; the company serves pediatric and adult patients worldwide through a network of surgeons, audiologists, and healthcare providers. Founded in Australia in 1981 and headquartered in Sydney, Cochlear operates in over 100 countries across North America, Europe, Asia-Pacific, and Latin America, holding more than 90% market share in the global cochlear implant segment. In recent developments, the company launched the next-generation Nucleus 12 sound processor in 2025, featuring enhanced AI-driven noise reduction and Bluetooth LE Audio compatibility; formed a strategic partnership with Medtronic in 2024 to advance minimally invasive implantation techniques; and completed the acquisition of Custom Hearing Solutions in early 2025 to expand personalized 3D-printed audio components.

Company News

APIChatGPT

  • defenseworld.net

    Cochlear Limited (OTCMKTS:CHEOF) Short Interest Update